Literature DB >> 17050664

Genetic and expression aberrations of E3 ubiquitin ligases in human breast cancer.

Ceshi Chen1, Arun K Seth, Andrew E Aplin.   

Abstract

Recent studies revealed that E3 ubiquitin ligases play important roles in breast carcinogenesis. Clinical research studies have found that (epi)-genetic (deletion, amplification, mutation, and promoter methylation) and expression aberration of E3s are frequent in human breast cancer. Furthermore, many studies have suggested that many E3s are either oncogenes or tumor suppressor genes in breast cancer. In this review, we provide a comprehensive summary of E3s, which have genetic and/or expression aberration in breast cancer. Most cancer-related E3s regulate the cell cycle, p53, transcription, DNA repair, cell signaling, or apoptosis. An understanding of the oncogenic potential of the E3s may facilitate identifying and developing individual E3s as diagnosis markers and drug targets in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17050664     DOI: 10.1158/1541-7786.MCR-06-0182

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  33 in total

1.  Role of the BCA2 ubiquitin E3 ligase in hormone responsive breast cancer.

Authors:  Angelika M Burger; Fathima Kona; Yutaka Amemiya; Yuguang Gao; Stephanie Bacopulos; Arun K Seth
Journal:  Open Cancer J       Date:  2010

Review 2.  E3 ubiquitin ligases in ErbB receptor quantity control.

Authors:  Kermit L Carraway
Journal:  Semin Cell Dev Biol       Date:  2010-09-22       Impact factor: 7.727

3.  Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33.

Authors:  Bert Gold; Tomas Kirchhoff; Stefan Stefanov; James Lautenberger; Agnes Viale; Judy Garber; Eitan Friedman; Steven Narod; Adam B Olshen; Peter Gregersen; Kristi Kosarin; Adam Olsh; Julie Bergeron; Nathan A Ellis; Robert J Klein; Andrew G Clark; Larry Norton; Michael Dean; Jeff Boyd; Kenneth Offit
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-07       Impact factor: 11.205

4.  Identification of FBXO25-interacting proteins using an integrated proteomics approach.

Authors:  Felipe R Teixeira; Sami Yokoo; Carlos A Gartner; Adriana O Manfiolli; Munira M A Baqui; Eliana M Assmann; Ana Leticia G C Maragno; Huijun Yu; Primal de Lanerolle; Jörg Kobarg; Steven P Gygi; Marcelo Damário Gomes
Journal:  Proteomics       Date:  2010-08       Impact factor: 3.984

5.  Adhesion-dependent Skp2 transcription requires selenocysteine tRNA gene transcription-activating factor (STAF).

Authors:  Ivette Hernández-Negrete; Graciela B Sala-Newby; Andras Perl; Gary R Kunkel; Andrew C Newby; Mark Bond
Journal:  Biochem J       Date:  2011-05-15       Impact factor: 3.857

6.  Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1.

Authors:  Hyun-Soo Cho; John D Kelly; Shinya Hayami; Gouji Toyokawa; Masahi Takawa; Masanori Yoshimatsu; Tatsuhiko Tsunoda; Helen I Field; David E Neal; Bruce Aj Ponder; Yusuke Nakamura; Ryuji Hamamoto
Journal:  Neoplasia       Date:  2011-08       Impact factor: 5.715

Review 7.  The ubiquitin-proteasome pathway in Huntington's disease.

Authors:  Steven Finkbeiner; Siddhartha Mitra
Journal:  ScientificWorldJournal       Date:  2008-04-20

Review 8.  The ubiquitin proteasome system in neuropathology.

Authors:  Norman L Lehman
Journal:  Acta Neuropathol       Date:  2009-07-14       Impact factor: 17.088

9.  Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer.

Authors:  Zi Liu; Liang Ma; Zhe-Sheng Wen; Zheng Hu; Fu-Qun Wu; Wei Li; Jinsong Liu; Guang-Biao Zhou
Journal:  Carcinogenesis       Date:  2013-11-30       Impact factor: 4.944

10.  Argonaute-2 expression is regulated by epidermal growth factor receptor and mitogen-activated protein kinase signaling and correlates with a transformed phenotype in breast cancer cells.

Authors:  Brian D Adams; Kevin P Claffey; Bruce A White
Journal:  Endocrinology       Date:  2008-09-11       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.